<unk>  is an experimental drug that is under clinical trials for the treatment of HIV-1 infections.<unk>  is synthetic peptide that binds to HIV-1's hydrophobic fusion peptide gp41, preventing the<unk> us from inserting itself into a host cell's membrane to initiate an infection. This drug is a synthesized variant of a highly specific natural entry inhibitor designated as<unk> IP <unk> us-inhibitory peptide). The design of<unk>  was based on<unk> IP which in turn was discovered in 2007 by Frank Kirchhoff and coworkers. This product is being developed by<unk> O Pharmaceuticals GmbH & Co. KG.
VIR-576
BGR-34
NFPA 704
GRAd-COV2
C-KAD
COVAX-19
SRD5A3-CDG
CURB-65